468 related articles for article (PubMed ID: 25470094)
21. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.
Kornstein S; Chang CT; Gommoll CP; Edwards J
Int Clin Psychopharmacol; 2018 Jul; 33(4):217-223. PubMed ID: 29608461
[TBL] [Abstract][Full Text] [Related]
22. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
Khan A
Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
[TBL] [Abstract][Full Text] [Related]
23. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
Findling RL; McCusker E; Strawn JR
J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
[No Abstract] [Full Text] [Related]
24. Vilazodone for the treatment of major depressive disorder.
Iranikhah M; Wensel TM; Thomason AR
Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.
Durgam S; Gommoll C; Forero G; Nunez R; Tang X; Mathews M; Sheehan DV
J Clin Psychiatry; 2016 Dec; 77(12):1687-1694. PubMed ID: 27232052
[TBL] [Abstract][Full Text] [Related]
26. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
27. Vilazodone: a novel antidepressant.
Choi E; Zmarlicka M; Ehret MJ
Am J Health Syst Pharm; 2012 Sep; 69(18):1551-7. PubMed ID: 22935937
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
[TBL] [Abstract][Full Text] [Related]
29. Vilazodone for the treatment of depression.
Lindsey WT
Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
[TBL] [Abstract][Full Text] [Related]
30. Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial.
Durgam S; Gommoll C; Migliore R; Chen C; Chang CT; Aguirre M; Thase ME
Int Clin Psychopharmacol; 2018 Nov; 33(6):304-311. PubMed ID: 30044247
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
32. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.
Gommoll C; Durgam S; Mathews M; Forero G; Nunez R; Tang X; Thase ME
Depress Anxiety; 2015 Jun; 32(6):451-9. PubMed ID: 25891440
[TBL] [Abstract][Full Text] [Related]
34. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.
Shi L; Wang J; Xu S; Lu Y
Drug Des Devel Ther; 2016; 10():3899-3907. PubMed ID: 27932864
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
[TBL] [Abstract][Full Text] [Related]
39. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
40. Vilazodone: a review in major depressive disorder in adults.
McCormack PL
Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
